Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

Blood

Volumn 117, Issue 24, 2011, Pages 6638-6649

  Kamper, Peter ^a   Ludvigsen, Maja ^b   Bendix, Knud ^a   Hamilton Dutoit, Stephen ^a   Rabinovich, Gabriel A ^c   Møller, Michael Boe ^d   Nyengaard, Jens R ^a   Honoré, Bent ^b   D'Amore, Francesco ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CARBOHYDRATE BINDING PROTEIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GALECTIN 1; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; CORRELATION COEFFICIENT; EVENT FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

EID: 79959273087     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-327346     Document Type: Article

References (43)

1. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
2. Fermé C, Mounier N, Casasnovas O, et al. Longterm results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006; 107(12):4636-4642. (Pubitemid 43882608)
3. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
4. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.; Spanish Hodgkin Lymphoma Study Group. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-668. (Pubitemid 44061368)
5. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
6. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1(4):304-313.
7. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-2346. (Pubitemid 351451442)
8. Wallentine JC, Kim KK, Seiler CE III, et al. Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LCMS/ MS. Lab Invest. 2007;87(11):1113-1124. (Pubitemid 47609024)
9. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9(5):338-352.
10. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5(3):241-251. (Pubitemid 38402116)
11. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007;110(4):1326-1329. (Pubitemid 47281432)
12. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007;104(32):13134-13139. (Pubitemid 351737605)
13. Rodig SJ, Ouyang J, Juszczynski P, et al. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008;14(11):3338-3344.
14. Stein H, Delsol G, Pileri S. Classical Hodgkin lymphoma pathology and genetics of tumours of haemopoeitic and lymphoid tissues. Lyon, France: IARC Press; 2001:244-253.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
16. Honoré B, Ostergaard M, Vorum H. Functional genomics studied by proteomics. Bioessays. 2004;26(8):901-915. (Pubitemid 39128104)
17. Vorum H, Ostergaard M, Hensechke P, Enghild JJ, Riazati M, Rice GE. Proteomic analysis of hyperoxia-induced responses in the human choriocarcinoma cell line JEG-3. Proteomics. 2004;4(3):861-867. (Pubitemid 38339163)
18. Mortz E, Krogh TN, Vorum H, Gorg A. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ ionization-time of flight analysis. Proteomics. 2001;1(11):1359- 1363. (Pubitemid 33587891)
19. Honoré B, Buus S, Claesson MH. Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53. Proteome Sci. 2008;6:18.
20. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20(18):3551-3567. (Pubitemid 30007252)
21. Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ. 2009;16(12):1573-1581.
22. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790-803.
23. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics. 2005;5(2):566-571. (Pubitemid 40262073)
24. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117(2):259-267. (Pubitemid 34823667)
25. Tzankov A, Went P, Zimpfer A, Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol. 2005;40(8-9):737-744. (Pubitemid 41265824)
26. Gundersen HJ, Bagger P, Bendtsen TF, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988;96(10):857-881.
27. Barrionuevo P, Beigier-Bompadre M, Ilarregui JM, et al. A novel function for galectin-1 at the cross-road of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol. 2007;178(1):436-445. (Pubitemid 46033627)
28. Correa SG, Sotomayor CE, Aoki MP, Maldonado CA, Rabinovich GA. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology. 2003;13(2):119-128. (Pubitemid 36504021)
29. Ilarregui JM, Croci DO, Bianco GA, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 2009;10(9):981-991.
30. Garín MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109(5):2058-2065. (Pubitemid 46348206)
31. Duncan MW, Hunsucker SW. Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp Biol Med (Maywood). 2005; 230(11):808-817. (Pubitemid 41785880)
32. Antonucci F, Chilosi M, Santacatterina M, Herbert B, Righetti PG. Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis. 2002;23(2):356-362. (Pubitemid 34157104)
33. Antonucci F, Chilosi M, Parolini C, Hamdan M, Astner H, Righetti PG. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis. 2003;24(14):2376-2385. (Pubitemid 38089023)
34. Smith C, Beagley L, Khanna R. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol. 2009;83(12):6192-6198.
35. Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 2007;8(8):825-834. (Pubitemid 47099035)
36. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96(2):269-276.
37. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011;96(2):186-189.
38. Shau H, Gupta RK, Golub SH. Identification of a natural killer enhancing factor (NKEF) from human erythroid cells. Cell Immunol. 1993;147(1):1-11. (Pubitemid 23100961)
39. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424(6948):561-565. (Pubitemid 36975778)
40. Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar MG. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol. 2008; 182(2):381-393.
41. Van Haastert PJ, Devreotes PN. Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol. 2004;5(8):626-634. (Pubitemid 39025063)
42. Aldinucci D, Gloghini A, Pinto A, De FR, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248-263.
43. Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol. 2010;22(5): 424-430.